Drew Armstrong of Bloomerg covered results from recent study looking at men whose prostate cancer relapsed and delayed hormone theraphy treatment. The researchers used a 14,000-patient database from University of California at San Francisco called CaPSURE that tracks men with prostate cancer to assess the benefits of the therapy. Click here for story,